Used as an intermediate in the synthesis of sulfa-based pharmaceuticals, particularly in the development of carbonic anhydrase inhibitors. These inhibitors are applied in the treatment of glaucoma, epilepsy, and certain types of edema. The compound’s structure allows for effective binding to enzyme active sites, enhancing its pharmacological activity. Also explored for its potential in anticancer research due to its ability to modulate tumor-associated carbonic anhydrase isoforms.